Key Insights

Highlights

Treatment Research

2 treatments under study, led by Oncological Followup

Research Leaders

5 sponsors active, led by Canceropôle Nord Ouest

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05500391Phase 2Recruiting

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

NCT00226798Phase 2UnknownPrimary

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Showing all 2 trials

Research Network

Common Treatments

  • Oncological Followup1
  • Capecitabine1

Active Sponsors

  • Canceropôle Nord Ouest1
  • Rambam Health Care Campus1
  • Roche Pharma AG1
  • Groupement Interrégional de Recherche Clinique et d'Innovation1
  • Centre Oscar Lambret1

Top Investigators

Related Conditions

  • Carcinosarcoma Ovarian1
  • Aggressive Fibromatosis Of Abdominal Wall Disorder1
  • Mucinous Adenocarcinoma Of Ovary1
  • Gastrointestinal Stromal Tumors1
  • Neuroendocrine Tumors1

Activity Timeline